Is CYTK a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

772 people get CYTK articles and Market Currents by email alert.

Get email alerts on CYTK »

HEADLINES:

SmithOnStocks Opines On Recent Biotech News
Smith On Stocks • Mon, May 13 • 8 Comments
Cytokinetics' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Tue, Apr 30
2 High Risk Biotech Stocks Under $2 That Could Yield A High Reward
C.R. Jackson • Wed, Apr 17 • 5 Comments
Cytokinetics: Key Issues For Beginning Phase III For Omecamtiv Mecarbil In Congestive Heart Failure
Smith On Stocks • Thu, Apr 11 • 4 Comments
Cytokinetics Growth-By-Partnership Strategy Looks Viable When It Comes To CK-2127107
Heather Ingrassia • Tue, Apr 2 • 4 Comments
Cytokinetics: Critical Phase IIb Data Is Upcoming In 2013 For Omecamtiv Mecarbil And Tirasemtiv
Smith On Stocks • Mon, Mar 25 • 9 Comments
George Zavoico: Biotech Stocks That Deserve A Closer Look
Life Sciences Report • Fri, Mar 8 • 1 Comment
Cytokinetics' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Tue, Feb 5
Cytokinetics' New Rally Pauses On Buyer Exhaustion
Brian L. Wilson • Fri, Jan 18 • 14 Comments
Cytokinetics' CEO Presents at Lazard Capital Markets Healthcare Conference (Transcript)
Tue, Nov 13, 2012
Cytokinetics' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Tue, Oct 30, 2012
Cytokinetics' CEO Discusses Q2 2012 Results - Earnings Call Transcript
Tue, Jul 31, 2012 • 1 Comment
Cytokinetics, Incorporated Reports Second Quarter 2012 Financial Results

Marketwire (Jul 31, 2012)
Cytokinetics Announces Heart Failure Program Update

Marketwire (Jul 26, 2012)
Cytokinetics to Announce Second Quarter Results on July 31, 2012

Marketwire (Jul 24, 2012)
Cytokinetics to Present at 7th Annual JMP Securities Healthcare Conference

Marketwire (Jul 5, 2012)
Cytokinetics, Incorporated Announces $60 Million Financing

Marketwire (Jun 20, 2012)
Cytokinetics Announces Proposed Public Offerings of Common Stock and Warrants and Series B Convertible Preferred Stock and Warrants

Marketwire (Jun 19, 2012)
Cytokinetics, Incorporated Receives NASDAQ Notice of Minimum Bid Price Non-Compliance

Marketwire (Jun 19, 2012)
Cytokinetics Announces Publication of Phase II Evidence of Effect Study of CK-2017357 in the Journal Amyotrophic Lateral Sclerosis

Marketwire (Jun 12, 2012)

To learn more about Seeking Alpha Pro, click here.

Cytokinetics: Key Issues For Beginning Phase III For Omecamtiv Mecarbil In Congestive Heart Failure
Smith On Stocks • Thu, Apr 11 • 4 Comments
Cytokinetics Growth-By-Partnership Strategy Looks Viable When It Comes To CK-2127107
Heather Ingrassia • Tue, Apr 2 • 4 Comments
Cytokinetics: Critical Phase IIb Data Is Upcoming In 2013 For Omecamtiv Mecarbil And Tirasemtiv
Smith On Stocks • Mon, Mar 25 • 9 Comments
Cytokinetics' New Rally Pauses On Buyer Exhaustion
Brian L. Wilson • Fri, Jan 18 • 14 Comments
Cytokinetics' Promising Pipeline: Value Stock for a Long-Term Investor
J.P. Zaragoza • Wed, Jul 20, 2011 • 4 Comments
Cytokinetics ALS Data Raises Hopes, May Be Onto Something
EP Vantage • Wed, Dec 15, 2010 • 1 Comment
Cytokinetics' Market Potential
Prohost Biotech • Thu, Nov 12, 2009 • 3 Comments

SmithOnStocks Opines On Recent Biotech News
Smith On Stocks • Mon, May 13 • 8 Comments
2 High Risk Biotech Stocks Under $2 That Could Yield A High Reward
C.R. Jackson • Wed, Apr 17 • 5 Comments
George Zavoico: Biotech Stocks That Deserve A Closer Look
Life Sciences Report • Fri, Mar 8 • 1 Comment
16 Small Caps With Cash to Cover 1+ Years of Operating Expenses
Kapitall • Wed, Apr 20, 2011 • 2 Comments
22 Companies With Market Cap Over $50 Million and 100%-Plus Sales Growth Forecast for 2011-12
Rash Menaria • Mon, Feb 28, 2011 • 8 Comments
Cytokinetics/Amgen Plan Boosts Optimism for Heart Failure Drug
Prohost Biotech • Wed, Feb 9, 2011
Value Trap or Play? 12 Smallcaps Hitting New Lows
The Keating Letter • Thu, Jan 20, 2011 • 11 Comments
Cytokinetics: Most Recent Victim of Unjustified Biotech Sell-Off
Prohost Biotech • Sun, Dec 19, 2010 • 11 Comments
Monday Options Update: CYTK, SNDK, XCO, GIII & CFN
Interactive Brokers • Mon, Dec 13, 2010
Cytokinetics Poised for Uptick in 2011
Sheff Station • Tue, Dec 7, 2010 • 4 Comments
15 Biotech Stocks With the Lowest Put/Call Ratios
Kapitall • Wed, Oct 13, 2010 • 3 Comments
Making and Breaking Biotech Deals
The Burrill Report • Mon, Dec 14, 2009
Biotech's Latest Failed Trials, Missed Targets
The Burrill Report • Mon, Dec 14, 2009 • 2 Comments
Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers
Justin M. Hall • Sun, Sep 20, 2009 • 18 Comments
Cash for Cardiovascular: Who Might Be Next?
Michael Becker • Wed, Aug 12, 2009 • 1 Comment
Two Potential Mega Biotech Deals Fuel Industry Hopes
The Burrill Report • Sun, May 31, 2009 • 2 Comments
FDA, Clinical Trial Updates: MAP Pharma, Cytokinetics, Hemispherx Post Big Gains
Mike Havrilla • Wed, May 27, 2009 • 2 Comments
3 Top and Bottom Market Sectors for This Week
J Clinton Hill • Tue, Dec 30, 2008 • 2 Comments
Navigating the Micro-Cap Biotech Minefield
Mike Havrilla • Sun, Nov 23, 2008 • 2 Comments
Cancer Stocks Slide Again
Alan Brochstein • Mon, Jun 18, 2007 • 1 Comment

Cytokinetics' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Tue, Apr 30
Cytokinetics' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Tue, Feb 5
Cytokinetics' CEO Presents at Lazard Capital Markets Healthcare Conference (Transcript)
Tue, Nov 13, 2012
Cytokinetics' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Tue, Oct 30, 2012
Cytokinetics' CEO Discusses Q2 2012 Results - Earnings Call Transcript
Tue, Jul 31, 2012 • 1 Comment
Cytokinetics CEO Discusses Q3 2010 Results - Earnings Call Transcript
Thu, Oct 28, 2010
Cytokinetics Inc. Q2 2010 Earnings Call Transcript
Thu, Jul 29, 2010
Cytokinetics Inc. Q1 2010 Earnings Call Transcript
Mon, May 3, 2010
Cytokinetics Inc. Q4 2009 Earnings Call Transcript
Wed, Feb 3, 2010
Cytokinetics, Inc. Q1 2009 Earnings Call Transcript
Thu, Apr 30, 2009
Cytokinetics, Inc. Q4 2008 Earnings Call Transcript
Tue, Feb 10, 2009
Cytokinetics Inc., Business Update Call Transcript
Mon, Mar 31, 2008
Cytokinetics Q3 2007 Earnings Call Transcript
Wed, Oct 31, 2007

Cytokinetics, Incorporated Reports Second Quarter 2012 Financial Results

Marketwire (Jul 31, 2012)
Cytokinetics Announces Heart Failure Program Update

Marketwire (Jul 26, 2012)
Cytokinetics to Announce Second Quarter Results on July 31, 2012

Marketwire (Jul 24, 2012)
Cytokinetics to Present at 7th Annual JMP Securities Healthcare Conference

Marketwire (Jul 5, 2012)
Cytokinetics, Incorporated Announces $60 Million Financing

Marketwire (Jun 20, 2012)
Cytokinetics Announces Proposed Public Offerings of Common Stock and Warrants and Series B Convertible Preferred Stock and Warrants

Marketwire (Jun 19, 2012)
Cytokinetics, Incorporated Receives NASDAQ Notice of Minimum Bid Price Non-Compliance

Marketwire (Jun 19, 2012)
Cytokinetics Announces Publication of Phase II Evidence of Effect Study of CK-2017357 in the Journal Amyotrophic Lateral Sclerosis

Marketwire (Jun 12, 2012)
Cytokinetics Announces Opening of Second Cohort in Phase IIb Clinical Trial of Intravenous Omecamtiv Mecarbil in Patients With Acute Heart Failure

Marketwire (May 24, 2012)
Cytokinetics to Hold Annual Meeting of Stockholders

Marketwire (May 15, 2012)
Cytokinetics Announces Company Participation and Support of ALS Fundraising Activities in Connection With ALS Awareness Month

Marketwire (May 9, 2012)
Cytokinetics, Incorporated Reports First Quarter 2012 Financial Results

Marketwire (Apr 26, 2012)
Cytokinetics Announces Presentation of Preclinical Data Regarding CK-2017357 at the 2012 Experimental Biology Annual Conference

Marketwire (Apr 26, 2012)
Cytokinetics Announces Encouraging Results From Two Phase II Clinical Trials Evaluating CK-2017357 in Patients With Amyotrophic Lateral Sclerosis

Marketwire (Apr 25, 2012)
Cytokinetics to Announce First Quarter Results on April 26, 2012

Marketwire (Apr 19, 2012)
Cytokinetics Announces CK-2017357 Receives Fast Track Designation From the FDA for the Potential Treatment of Amyotrophic Lateral Sclerosis

Marketwire (Apr 19, 2012)
Cytokinetics Announces Clinical Trial Data Relating to CK-2017357 to Be Presented at the 64th Annual Meeting of the American Academy of Neurology

Marketwire (Apr 18, 2012)
Cytokinetics to Present at the Eleventh Annual Needham Life Sciences Conference

Marketwire (Mar 27, 2012)
Cytokinetics to Announce Fourth Quarter and Year End Results on February 2, 2012

Marketwire (Jan 26, 2012)
Biotech Stocks: Drug indexes hug the flat line

at MarketWatch.com (Dec 13, 2010)

CYTK vs. ETF Alternatives

Company Description

We were incorporated in Delaware in August 1997 as Cytokinetics, Incorporated. We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Monday, April 1, 11:31 AM Cytokinetics (CYTK -1.8%) says it's begun a first-time-in-humans, Phase I clinical trial of CK-2127107, a potential treatment for improving skeletal muscle function in diseases and medical conditions associated with neuromuscular dysfunction, muscular weakness, and/or muscle fatigue. Comment! [Healthcare, On the Move]
Thursday, March 21, 1:40 PM Cytokinetics (CYTK -1%) reports positive data from a completed Phase IIa "Evidence of Effect" clinical trial of tirasemtiv, its lead drug candidate from the company's skeletal muscle contractility program, in patients with generalized myasthenia gravis. Tirasemtiv creates an increasing its sensitivity to calcium in the skeletal system, which delays the onset and reduces the degree of muscle fatigue. The results from the study were presented during the Emerging Science Program at the 65th Annual Meeting of the American Academy of Neurology. Comment! [Healthcare]
Wednesday, February 6, 6:24 AM Cytokinetics (CYTK): Q4 EPS of -$0.07 beats by $0.04. Revenue of $2.2M beats by $1M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, February 4, 12:45 PM Midday top 10 gainers: HPTX +31%. APKT +22%. EBOD +16%. PGRX +15%. SONS +14%. PC +11%. EDAP +9%. ORRF +10%. HMY +9%. TAOM +9%.
Midday top 10 Losers: INUV -13%. CLSN -13%. SED -12%. CYTK -8%. VVI -9%. CTC -8%. PRIS -8%. PERI -8%. BLIN -8%. CFBK -8%. Comment! [On the Move]
Friday, January 25, 4:11 PM Cytokinetics (CYTK) says it's received notice from The Nasdaq Stock Market confirming that for the last 10 consecutive business days, the closing bid price of its stock has been at $1.00 per share or greater, therby regained compliance with listing rules. Comment! [Healthcare]
Friday, January 4, 4:23 PM Cytokinetics (CYTK +14%) finishes the day firmly in the black after Piper Jaffray initiated the shares earlier today with an Overweight and a $4.00 price target. Piper noted the company's platform for treating diseases by improving muscle function is under-appreciated due to its novelty. Additionally, positive data in its Phase II study for tirasemtiv, a treatment for amyotropic lateral sclerosis. could lead to a partnership or buy-out in 2013. Comment! [Healthcare, On the Move]
Monday, November 26, 2012, 4:06 PM Cytokinetics (CYTK +1.5%) finishes higher after reporting positive Phase IIa data of its drug candidate tirasemtiv, a treatment for patients with generalized myasthenia gravis. The drug is also is seen as a potential treatment for amyotrophic lateral sclerosis. Comment! [Healthcare, On the Move]
Tuesday, March 6, 2012, 1:38 PM Cytokinetics (CYTK +6.7%) pops after saying the European Medicines Agency has granted its drug CK-2017357, its fast skeletal muscle troponin activator, orphan medicinal product designation for the treatment of Lou Gehrig's Disease. Comment! [On the Move, Healthcare, Global & FX]
Tuesday, March 6, 2012, 9:05 AM Premarket gainers: VRML +14%. HNR +12%. CYTK +10%. NBG +8%. MWW +7%.
Losers: ONTY -40%. ZLTQ -14%. AEZS -12%. NTRI -11%. KERX -8%. RAS -6%. VVUS -6%. CNX -5%. Comment! [On the Move]
Tuesday, October 18, 2011, 5:58 PM Bio-researcher Cytokinetics (CYTK) says it's cutting its work force and narrowing its resources to better focus on the development of its heart failure and muscular dysfunction treatments. Shares +1% AH. Comment! [Healthcare]
Thursday, October 13, 2011, 2:12 PM Cytokinetics (CYTK +2.5%) gains after Rodman & Renshaw initiates it with an outperform, saying the stock is "markedly undervalued," and a pure play in muscle biology that is "awaiting rediscovery by the investment community.” Comment! [Healthcare, On the Move, Quick Ideas]
Tuesday, September 27, 2011, 3:24 PM Cytokinetics (CYTK +9%) trades higher late in the day after it says pre-clinical research relating to its program directed to the inhibition of smooth muscle myosin as a therapeutic approach for the potential treatment of hypertension has been published in the October issue of The Journal of Pharmacology and Experimental Therapeutics. Comment! [Healthcare, On the Move]
Tuesday, June 2, 2009, 9:00 AM Premarket gainers: NTG +18%. DDUP +18%. CYTK +12%. UFS +8%. SAY +7%. UNFI +7%. PAY +6%. CAL +4%. DSCO +4%.
Losers: BCS -13%. CBL -12%. MTZ -11%. CTIC -6%. PLD -5%. MS -5%. KEY -4%. AXP -4%. Comment!
Wednesday, May 27, 2009, 9:00 AM Premarket gainers: MAPP +13%. SNDK +13%. SQNM +12%. HEB +6%. RF +4%. CYTK +4%. CHS +4%. CIT +4%. THC +4%.
Losers: SEED -18%. GM -12%. HIW -6%. MON -4%. SYT -4%. Comment!
Tuesday, May 26, 2009, 9:01 AM Premarket gainers: MAPP +138%. CYTK +46%. BNC +15%. CPST +13%. HEB +12%. OXGN +9%. UTHR +8%. FEED +7%. Q +6%. ALTI +5%. ARNA +4%.
Losers: TMS +13%. CIM -10%. AIB -7%. GM -6%. CSIQ -6%. FSLR -5%. AIG -5%. DNN -5%. VE -4%. Comment!

The Scientist
RS is almost never a good thing for stocks. As long as Omecamtiv and Tirasemtiv trials go well, $CYTK will be ok
Apr 11, 8:29 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Scientist
Even if $CYTK does RS, not too bad. Most important - both of their drugs succeed in trials. If drugs succeed, $CYTK will do just fine.
Apr 3, 1:25 PM
Reply (1)

• !Report Abuse
View all 1 replies
Michael Webb: Purpose of reverse split: another round of dilutive stock offerings to hedge their bets on an Amgen pullout. That's a problem.
Apr 11, 3:37 PM
• !Report Abuse
Add a reply...

140 characters

Michael Webb
$CYTK Cytokinetics is going to shareholders suggesting the need for a reverse stock split. http://bit.ly/10oOmya Vote No! Thank you
Apr 3, 2:03 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Scientist
Tirasemtiv P2b trial for ALS really a P3! $CYTK stated many times they will go to FDA for drug approval if + results.
Mar 25, 1:12 PM
Reply (1)

• !Report Abuse
View all 1 replies
Michael Webb: This is my riskiest biotech investment. I hope it goes well as I continue to purchase shares. You can feel the apprehension. Go Cyto!
Apr 1, 5:48 AM
• !Report Abuse
Add a reply...

140 characters

The Scientist
Thank you very much Mr. Smith for the great article on $CYTK. Given its pipeline and $AMGN partnership, still ridiculously undervalued!
Mar 25, 12:59 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Scientist
$CYTK still ridiculously undervalued. Current levels give no real value to pipeline. Near total failure priced in.
Mar 3, 9:21 PM
Reply (3)

• !Report Abuse
View all 3 replies
The Scientist: Wall St totally ignoring CYTK. Exact same thing happened with SRPT. SRPT was way below $1 for a long time before getting noticed.
Mar 19, 4:28 AM
• !Report Abuse
Michael Webb: Buying shares today. Fabulous presentation at the 25th annual Roth Conference you can find here: http://bit.ly/137bF4l
Mar 19, 5:09 AM
• !Report Abuse
Add a reply...

140 characters

The Scientist
No other heart failure drug can do what $CYTK Omecamtiv can: raise SV, lower BP/HR. If proven safe, a true miracle drug. Gives HF pts hope.
Mar 3, 9:17 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Scientist
Looking forward to $CYTK presentation at American College of Cardiology meeting next weekend. Omecamtiv will transform heart failure tx
Mar 1, 12:00 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Scientist
Article on SA talks about buyer exhaustion for $CYTK. Nice call. $CYTK has just started this rally. Drugs with $multibillion potential.
Jan 29, 11:50 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Scientist
If $CYTK can get above the $3 level, will then start to see some real buying action from big institutional investors.
Jan 24, 9:06 PM
Reply (1)

• !Report Abuse
View all 1 replies
The Scientist: Vanguard, Fidelity, Deutsche Bank and T Rowe Price already on board as major shareholders.
Jan 24, 9:09 PM
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

The Scientist
Even if $CYTK does RS, not too bad. Most important - both of their drugs succeed in trials. If drugs succeed, $CYTK will do just fine.
Apr 3, 1:25 PM
Reply (1)

• !Report Abuse
View all 1 replies
Michael Webb: Purpose of reverse split: another round of dilutive stock offerings to hedge their bets on an Amgen pullout. That's a problem.
Apr 11, 3:37 PM
• !Report Abuse
Add a reply...

140 characters

The Scientist
Tirasemtiv P2b trial for ALS really a P3! $CYTK stated many times they will go to FDA for drug approval if + results.
Mar 25, 1:12 PM
Reply (1)

• !Report Abuse
View all 1 replies
Michael Webb: This is my riskiest biotech investment. I hope it goes well as I continue to purchase shares. You can feel the apprehension. Go Cyto!
Apr 1, 5:48 AM
• !Report Abuse
Add a reply...

140 characters

The Scientist
$CYTK still ridiculously undervalued. Current levels give no real value to pipeline. Near total failure priced in.
Mar 3, 9:21 PM
Reply (3)

• !Report Abuse
View all 3 replies
The Scientist: Wall St totally ignoring CYTK. Exact same thing happened with SRPT. SRPT was way below $1 for a long time before getting noticed.
Mar 19, 4:28 AM
• !Report Abuse
Michael Webb: Buying shares today. Fabulous presentation at the 25th annual Roth Conference you can find here: http://bit.ly/137bF4l
Mar 19, 5:09 AM
• !Report Abuse
Add a reply...

140 characters

The Scientist
If $CYTK can get above the $3 level, will then start to see some real buying action from big institutional investors.
Jan 24, 9:06 PM
Reply (1)

• !Report Abuse
View all 1 replies
The Scientist: Vanguard, Fidelity, Deutsche Bank and T Rowe Price already on board as major shareholders.
Jan 24, 9:09 PM
• !Report Abuse
Add a reply...

140 characters

The Scientist
CYTK management is doing a terrible job promoting their drugs. Have not heard ANY media coverage from their ALS or HF drugs
5/25/12
Reply (1)

• !Report Abuse
View all 1 replies
The Scientist: They should be promoting their company/results of the drug trials in ALS and HF to Bloomberg/CNBC/WSJ. Have not seen any media coverage.
5/25/12
• !Report Abuse
Add a reply...

140 characters

The Scientist
CYTK: Wall St completely ignoring great results of ALS and HF drugs. AMGN should just buy them out. Ridiculously undervalued at $70M
5/24/12
Reply (2)

• !Report Abuse
View all 2 replies
The Scientist: Omecamtiv is a wonder drug that can be used in the ICU like water. It raises CO/SV; lowers BP/HR. Too good to be true.
5/24/12
• !Report Abuse
briandiplacido: As a long-time ICU nurse who's seen tons of tachyarrythmia from inotropes, I agree (seems too good to be true). Interesting.
5/24/12
• !Report Abuse
Add a reply...

140 characters

The Scientist
CYTK Omecamtiv program has ridiculous potential. Currently NO good drugs for HF (big problems with SE's). IV HF drugs expensive $1k+/day
5/21/12
Reply (2)

• !Report Abuse
View all 2 replies
The Scientist: Market potential in US: 5M pts x $1K/day = very large potential. This is IF drug passes trials.
5/21/12
• !Report Abuse
iadops40: Sci, I have been eyeing CYTK, impressive pipeline. I'm a little concerned w/ such a small market cap. Whats their finance look like?
5/21/12
• !Report Abuse
Add a reply...

140 characters

The Scientist
CYTK ALS drug study was a huge breakthrough. 1st ALS drug that actually improves breathing/ADLs. Do not know what Wall St was expecting.
4/27/12
Reply (1)

• !Report Abuse
View all 1 replies
The Scientist: If you ever saw an ALS pt, you will understand that ANY improvement is remarkable. CYTK drug does improve their lives. Media coverage likely
4/27/12
• !Report Abuse
Add a reply...

140 characters

CYTK Cytokinetics, Incorporated

CYTK

Cytokinetics, Incorporated